CASE REPORT article
Front. Oncol.
Sec. Gastrointestinal Cancers: Gastric and Esophageal Cancers
Volume 15 - 2025 | doi: 10.3389/fonc.2025.1631062
This article is part of the Research TopicReal-World Clinical and Translational Research in Gastrointestinal CancersView all 12 articles
Complete Remission of Recurrent Gastric Cancer in a Young Female Patient through CLDN18.2-Targeted Therapy (LM302) and Metastatic Ovarian Tumor Resection: A Case Report of Refractory Disease Overcoming Chemotherapy and Immunotherapy Resistance
Provisionally accepted
- Nanjing Medical University, Nanjing, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Young patients with recurrent, metastatic gastric cancer (GC) resistant to chemotherapy and immunotherapy have poor outcomes and limited treatment options.CLDN18.2 has emerged as a promising target in GC. We report the case of a 35-yearold female who experienced recurrence with bilateral ovarian and lymph node metastases 16 months after radical gastrectomy and adjuvant chemotherapy. Multiple therapies failed, and CLDN18.2 expression was suspected. She enrolled in a Phase I/II trial of LM302, a CLDN18.2-targeted antibody-drug conjugate, receiving eight cycles.Imaging showed significant regression of lymph node lesions and stable ovarian metastases. In April 2024, she underwent laparoscopic resection of the ovarian tumors, with pathology confirming no residual disease. As of March 2025, she remains diseasefree with excellent performance status. This case illustrates that CLDN18.2-targeted therapy combined with surgery may offer curative potential in refractory GC and highlights the importance of biomarker-driven precision medicine.
Keywords: gastric cancer, CLDN18.2-Targeted Therapy, LM302, Ovarian metastasis, precision medicine
Received: 19 May 2025; Accepted: 31 Jul 2025.
Copyright: © 2025 Chen, Wang, Wang and Zhang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Tongshan Wang, Nanjing Medical University, Nanjing, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.